<p>Cardiol Therapeutics Inc. (TSE:CRDL - 獲取免費報告) 的股價在週二的午盤交易中下跌了 0.7%。該公司的股價最低曾達到 C$1.37，最後交易價為 C$1.39。在午盤交易中，共交易了 25,955 股，較平均交易量 107,933 股下降了 76%。該股票此前收盤價為 C$1.40。</p>
<p>獲取 <strong>Cardiol Therapeutics</strong> 的提醒：</p>
<h2>Cardiol Therapeutics 股票表現</h2>
<p>該公司的市值為 1.39 億加元，市盈率為-3.39，貝塔係數為 1.55。該股票的 50 日簡單移動平均線為 C$1.47，200 日簡單移動平均線為 C$1.61。該公司的速動比率為 6.84，流動比率為 2.49，債務與股本比率為 1.59。</p>
<p>Cardiol Therapeutics (TSE:CRDL - 獲取免費報告) 最近於 11 月 13 日（星期四）發佈了季度財報。該公司報告本季度每股收益為 C($0.12)。整體來看，研究分析師預計 Cardiol Therapeutics Inc.在當前年度的每股收益將為-0.49。</p>
<h2>Cardiol Therapeutics 公司簡介</h2>
<p>(獲取免費報告)</p>
<p>Cardiol Therapeutics Inc NASDAQ: CRDLTSX: CRDL 是一家臨牀階段的生命科學公司，專注於心髒病的抗炎和抗纖維化療法的研究與臨牀開發。公司的主要藥物候選者 CardiolRxTM（大麻二酚）口服溶液，經過藥品製造，正在進行臨牀開發以用於心臟病治療。已知大麻二酚能夠抑制炎症小體通路的激活，這一細胞內過程在與心肌炎、心包炎和心力衰竭相關的炎症和纖維化的發展與進展中起着重要作用。</p>
<h2>相關文章</h2>
<ul>
<li>我們更看好的五隻股票超過 Cardiol Therapeutics</li>
<li>可能每月支付高達$4,290 的無聊 AI 投資</li>
<li>在 1 月 1 日之前投資$1,000 於這隻股票 [不是 NVDA]</li>
<li>特朗普的 “美國房地產交易” 解釋</li>
<li>崩盤前一個月</li>
<li>特朗普做了什麼？？</li>
</ul>
<p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或評論發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資$1,000 於 Cardiol Therapeutics 嗎？</h2>
<p>在考慮 Cardiol Therapeutics 之前，你需要聽聽這個。</p>
<p>MarketBeat 跟蹤華爾街頂級評級和表現最佳的研究分析師及其每日推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師正在悄悄推薦給客户的股票，以便在更廣泛的市場注意到之前購買……而 Cardiol Therapeutics 並不在名單上。</p>
<p>雖然 Cardiol Therapeutics 目前在分析師中被評為持有評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

CRDL

<p>Cardiol Therapeutics Inc.（多倫多證券交易所代碼：CRDL）在週二的午盤交易中，股價下跌了 0.7%，至 1.39 加元，交易量顯著下降。該公司的市值為 1.39 億加元，專注於開發針對心臟病的抗炎和抗纖維化療法。儘管分析師給予了持有評級，但 Cardiol Therapeutics 並未被 MarketBeat 的頂級分析師推薦為前五大股票</p>

<p>Cardiol Therapeutics Inc. (TSE:CRDL - Get Free Report)'s share price traded down 0.7% during mid-day trading on Tuesday . The company traded as low as C$1.37 and last traded at C$1.39. 25,955 shares were traded during mid-day trading, a decline of 76% from the average session volume of 107,933 shares. The stock had previously closed at C$1.40.</p>
<div class="lb-trans"><p>Cardiol Therapeutics Inc. (TSE:CRDL - 獲取免費報告) 的股價在週二的午盤交易中下跌了 0.7%。該公司的股價最低曾達到 C$1.37，最後交易價為 C$1.39。在午盤交易中，共交易了 25,955 股，較平均交易量 107,933 股下降了 76%。該股票此前收盤價為 C$1.40。</p>
</div><p>Get <strong>Cardiol Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Cardiol Therapeutics</strong> 的提醒：</p>
</div><h2>Cardiol Therapeutics Stock Performance</h2>
<div class="lb-trans"><h2>Cardiol Therapeutics 股票表現</h2>
</div><p>The company has a market cap of C$139.00 million, a PE ratio of -3.39 and a beta of 1.55. The stock's 50 day simple moving average is C$1.47 and its two-hundred day simple moving average is C$1.61. The company has a quick ratio of 6.84, a current ratio of 2.49 and a debt-to-equity ratio of 1.59.</p>
<div class="lb-trans"><p>該公司的市值為 1.39 億加元，市盈率為-3.39，貝塔係數為 1.55。該股票的 50 日簡單移動平均線為 C$1.47，200 日簡單移動平均線為 C$1.61。該公司的速動比率為 6.84，流動比率為 2.49，債務與股本比率為 1.59。</p>
</div><p>Cardiol Therapeutics (TSE:CRDL - Get Free Report) last released its quarterly earnings data on Thursday, November 13th. The company reported C($0.12) EPS for the quarter. As a group, research analysts anticipate that Cardiol Therapeutics Inc. will post -0.49 earnings per share for the current year.</p>
<div class="lb-trans"><p>Cardiol Therapeutics (TSE:CRDL - 獲取免費報告) 最近於 11 月 13 日（星期四）發佈了季度財報。該公司報告本季度每股收益為 C($0.12)。整體來看，研究分析師預計 Cardiol Therapeutics Inc.在當前年度的每股收益將為-0.49。</p>
</div><h2>Cardiol Therapeutics Company Profile</h2>
<div class="lb-trans"><h2>Cardiol Therapeutics 公司簡介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>(獲取免費報告)</p>
</div><p>Cardiol Therapeutics Inc NASDAQ: CRDLTSX: CRDL is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease. The Company's lead drug candidate, CardiolRxTM (cannabidiol) oral solution, is pharmaceutically manufactured and in clinical development for use in the treatment of heart disease. It is recognized that cannabidiol inhibits activation of the inflammasome pathway, an intracellular process known to play an important role in the development and progression of inflammation and fibrosis associated with myocarditis, pericarditis, and heart failure.</p>
<div class="lb-trans"><p>Cardiol Therapeutics Inc NASDAQ: CRDLTSX: CRDL 是一家臨牀階段的生命科學公司，專注於心髒病的抗炎和抗纖維化療法的研究與臨牀開發。公司的主要藥物候選者 CardiolRxTM（大麻二酚）口服溶液，經過藥品製造，正在進行臨牀開發以用於心臟病治療。已知大麻二酚能夠抑制炎症小體通路的激活，這一細胞內過程在與心肌炎、心包炎和心力衰竭相關的炎症和纖維化的發展與進展中起着重要作用。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>相關文章</h2>
</div><ul>
<li>Five stocks we like better than Cardiol Therapeutics</li>
<li>The boring AI play that could pay up to $4,290 monthly</li>
<li>Put $1,000 into this stock by Jan 1 [Not NVDA]</li>
<li>Trump’s “real estate deal for America” explained</li>
<li>A month before the crash</li>
<li>Trump Did WHAT??</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票超過 Cardiol Therapeutics</li>
<li>可能每月支付高達$4,290 的無聊 AI 投資</li>
<li>在 1 月 1 日之前投資$1,000 於這隻股票 [不是 NVDA]</li>
<li>特朗普的 “美國房地產交易” 解釋</li>
<li>崩盤前一個月</li>
<li>特朗普做了什麼？？</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或評論發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Cardiol Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資$1,000 於 Cardiol Therapeutics 嗎？</h2>
</div><p>Before you consider Cardiol Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮 Cardiol Therapeutics 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cardiol Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 跟蹤華爾街頂級評級和表現最佳的研究分析師及其每日推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師正在悄悄推薦給客户的股票，以便在更廣泛的市場注意到之前購買……而 Cardiol Therapeutics 並不在名單上。</p>
</div><p>While Cardiol Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Cardiol Therapeutics 目前在分析師中被評為持有評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Cardiol Therapeutics (TSE:CRDL) 股價下跌 0.7% - 以下是原因